Published in J Immunol on June 01, 2008
The basic principles of chimeric antigen receptor design. Cancer Discov (2013) 3.28
Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med (2010) 2.92
Adoptive T cell therapy of cancer. Curr Opin Immunol (2010) 2.13
Treating cancer with genetically engineered T cells. Trends Biotechnol (2011) 1.83
Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol (2014) 1.61
T cell receptor gene therapy for cancer. Hum Gene Ther (2009) 1.17
Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains. Gene Ther (2011) 0.91
Molecular immunology lessons from therapeutic T-cell receptor gene transfer. Immunology (2010) 0.91
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu. Front Immunol (2013) 0.87
The past, present, and future of adoptive T cell therapy. Immune Netw (2012) 0.86
The Evolution of T-cell Therapies for Solid Malignancies. Clin Cancer Res (2015) 0.84
A Promising Vector for TCR Gene Therapy: Differential Effect of siRNA, 2A Peptide, and Disulfide Bond on the Introduced TCR Expression. Mol Ther Nucleic Acids (2012) 0.82
T-cell receptor gene transfer for the treatment of leukemia and other tumors. Haematologica (2010) 0.82
A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control. Cancer Immunol Immunother (2014) 0.81
Application of adoptive T-cell therapy using tumor antigen-specific T-cell receptor gene transfer for the treatment of human leukemia. J Biomed Biotechnol (2010) 0.81
How (specific) would like your T-cells today? Generating T-cell therapeutic function through TCR-gene transfer. Front Immunol (2012) 0.79
Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy. Arch Immunol Ther Exp (Warsz) (2010) 0.78
An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells. Oncotarget (2016) 0.78
Magnetic-activated cell sorting of TCR-engineered T cells, using tCD34 as a gene marker, but not peptide-MHC multimers, results in significant numbers of functional CD4+ and CD8+ T cells. Hum Gene Ther Methods (2012) 0.78
Building and optimizing a virus-specific T cell receptor library for targeted immunotherapy in viral infections. Sci Rep (2014) 0.77
TCR-engineered T cells: a model of inducible TCR expression to dissect the interrelationship between two TCRs. Eur J Immunol (2013) 0.77
Targeting melanoma with immunoliposomes coupled to anti-MAGE A1 TCR-like single-chain antibody. Int J Nanomedicine (2016) 0.75
Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities. Oncoimmunology (2017) 0.75
Generation of V α13/β21+T cell specific target CML cells by TCR gene transfer. Oncotarget (2016) 0.75
A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell (2009) 6.03
The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell (2011) 5.06
Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol (2006) 5.02
A MicroRNA targeting dicer for metastasis control. Cell (2010) 4.81
Recruitment of Nck by CD3 epsilon reveals a ligand-induced conformational change essential for T cell receptor signaling and synapse formation. Cell (2002) 2.94
Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med (2010) 2.92
Coexistence of multivalent and monovalent TCRs explains high sensitivity and wide range of response. J Exp Med (2005) 2.57
The Atx1-Ccc2 complex is a metal-mediated protein-protein interaction. Nat Chem Biol (2006) 2.56
CASD-NMR: critical assessment of automated structure determination by NMR. Nat Methods (2009) 2.50
SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature (2012) 2.46
Counting the zinc-proteins encoded in the human genome. J Proteome Res (2006) 2.38
Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood (2010) 2.31
Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet (2011) 2.29
Zinc through the three domains of life. J Proteome Res (2006) 2.11
A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood (2011) 2.03
Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treat Rev (2009) 2.00
T cell receptor internalization from the immunological synapse is mediated by TC21 and RhoG GTPase-dependent phagocytosis. Immunity (2011) 2.00
A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell (2011) 1.95
Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther (2013) 1.89
Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo. Cancer Immunol Immunother (2007) 1.86
Toll-like receptor 2 regulates intestinal inflammation by controlling integrity of the enteric nervous system. Gastroenterology (2013) 1.83
MTOC translocation modulates IS formation and controls sustained T cell signaling. J Cell Biol (2008) 1.75
Full activation of the T cell receptor requires both clustering and conformational changes at CD3. Immunity (2006) 1.72
T cell receptor engagement by peptide-MHC ligands induces a conformational change in the CD3 complex of thymocytes. J Exp Med (2005) 1.69
Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res (2005) 1.63
Quantitative imaging of the T cell antitumor response by positron-emission tomography. Proc Natl Acad Sci U S A (2003) 1.60
Metalloproteomes: a bioinformatic approach. Acc Chem Res (2009) 1.52
The Rho exchange factors Vav2 and Vav3 favor skin tumor initiation and promotion by engaging extracellular signaling loops. PLoS Biol (2013) 1.50
Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2. J Cell Sci (2002) 1.48
Bare lymphocyte syndrome: an opportunity to discover our immune system. Immunol Lett (2011) 1.45
The prolyl-isomerase Pin1 is a Notch1 target that enhances Notch1 activation in cancer. Nat Cell Biol (2009) 1.44
Tuberculous pleural effusions. Eur J Intern Med (2003) 1.43
Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cells. Cytotherapy (2013) 1.43
Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes. J Immunol (2003) 1.41
Solution structure and intermolecular interactions of the third metal-binding domain of ATP7A, the Menkes disease protein. J Biol Chem (2006) 1.40
Computer program for determining fluorescence resonance energy transfer efficiency from flow cytometric data on a cell-by-cell basis. Comput Methods Programs Biomed (2004) 1.33
CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol Med (2012) 1.32
Essential function for the GTPase TC21 in homeostatic antigen receptor signaling. Nat Immunol (2009) 1.30
HMGA1 promotes metastatic processes in basal-like breast cancer regulating EMT and stemness. Oncotarget (2013) 1.29
Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men. Hum Immunol (2004) 1.27
A hint to search for metalloproteins in gene banks. Bioinformatics (2004) 1.25
Occurrence of copper proteins through the three domains of life: a bioinformatic approach. J Proteome Res (2007) 1.24
MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res (2012) 1.22
An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol (2006) 1.21
Cytochrome c: occurrence and functions. Chem Rev (2006) 1.21
Role of Fyn in the rearrangement of tubulin cytoskeleton induced through TCR. J Immunol (2006) 1.20
Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells. J Immunol (2007) 1.15
Solution structure of the apo and copper(I)-loaded human metallochaperone HAH1. Biochemistry (2004) 1.13
Molecular design of the Calphabeta interface favors specific pairing of introduced TCRalphabeta in human T cells. J Immunol (2008) 1.12
Cooperativity between T cell receptor complexes revealed by conformational mutants of CD3epsilon. Sci Signal (2009) 1.11
Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors. Cancer Res (2009) 1.10
Antimicrobial activity of saponins from Medicago sp.: structure-activity relationship. Phytother Res (2006) 1.08
T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing. Trends Mol Med (2010) 1.07
Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. Immunol Lett (2005) 1.06
A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. Clin Cancer Res (2008) 1.06
Die hard: are cancer stem cells the Bruce Willises of tumor biology? Cytometry A (2009) 1.06
Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors. J Immunol (2010) 1.05
Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer. Eur J Cancer (2007) 1.04
An NMR study of the interaction of the N-terminal cytoplasmic tail of the Wilson disease protein with copper(I)-HAH1. J Biol Chem (2009) 1.04
Selection of human antibody fragments directed against tumor T-cell epitopes for adoptive T-cell therapy. Cytometry A (2008) 1.04
Ligand-induced conformational change in the T-cell receptor associated with productive immune synapses. Blood (2005) 1.04
Paramagnetically induced residual dipolar couplings for solution structure determination of lanthanide binding proteins. J Am Chem Soc (2002) 1.04
End-binding protein 1 controls signal propagation from the T cell receptor. EMBO J (2012) 1.04
Genetic engineering of T cell specificity for immunotherapy of cancer. Hum Immunol (2003) 1.04
Development of adoptive cell therapy for cancer: a clinical perspective. Hum Gene Ther (2010) 1.03
Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells. Cancer Immunol Immunother (2010) 1.03
Quantitative characterization of the large-scale association of ErbB1 and ErbB2 by flow cytometric homo-FRET measurements. Biophys J (2008) 1.02
RPF: a quality assessment tool for protein NMR structures. Nucleic Acids Res (2012) 1.02
T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production. J Immunol (2005) 1.01
A role for EZH2 in silencing of IFN-gamma inducible MHC2TA transcription in uveal melanoma. J Immunol (2007) 1.01
Predicting zinc binding at the proteome level. BMC Bioinformatics (2007) 1.01
An NMR study of the interaction between the human copper(I) chaperone and the second and fifth metal-binding domains of the Menkes protein. FEBS J (2005) 1.00
A conformation- and avidity-based proofreading mechanism for the TCR-CD3 complex. Trends Immunol (2006) 1.00
Evaluation of intensity-based ratiometric FRET in image cytometry--approaches and a software solution. Cytometry A (2009) 1.00
Genome-based analysis of heme biosynthesis and uptake in prokaryotic systems. J Proteome Res (2008) 1.00
A Grid-enabled web portal for NMR structure refinement with AMBER. Bioinformatics (2011) 0.99
EGFR and ErbB2 are functionally coupled to CD44 and regulate shedding, internalization and motogenic effect of CD44. Cancer Lett (2008) 0.99
Suppression of tumor growth and cell proliferation by p13II, a mitochondrial protein of human T cell leukemia virus type 1. Proc Natl Acad Sci U S A (2004) 0.99
T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies. Expert Opin Biol Ther (2010) 0.99
The functions of Sco proteins from genome-based analysis. J Proteome Res (2007) 0.99
AccPbFRET: an ImageJ plugin for semi-automatic, fully corrected analysis of acceptor photobleaching FRET images. BMC Bioinformatics (2008) 0.98
The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders. Haematologica (2010) 0.98
A systematic investigation of multiheme c-type cytochromes in prokaryotes. J Biol Inorg Chem (2010) 0.98
Solution structure and characterization of the heme chaperone CcmE. Biochemistry (2002) 0.98
A novel mutation in the upstream open reading frame of the CDKN1B gene causes a MEN4 phenotype. PLoS Genet (2013) 0.98